Melanotan II on the 2027 Docket: The Tanning Peptide's Safety Record and the Melanoma Question

Melanotan II is on the agenda for the FDA's next compounding advisory committee meeting, scheduled before the end of February 2027. It is the only compound on that slate with a documented record of consumer harm and a standing warning from a major dermatology organization.

That combination makes it worth writing about carefully, and worth writing about differently from everything else on the docket.

What it is

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone. It activates melanocortin receptors — primarily MC1R — which stimulates melanin production and darkens skin without UV exposure.

It was developed in the 1990s at the University of Arizona, originally explored as a potential skin cancer prevention agent. The logic was reasonable at the time: if you could produce protective pigmentation without sun exposure, you might reduce UV-driven cancer risk.

It has never been approved by any regulatory agency, anywhere, for any indication.

Where it sits regulatorily

Melanotan II was among the twelve peptides removed from the FDA's Category 2 list in April 2026, after the original nominations were withdrawn. Like most of that group, it did not move to Category 1 — it left the restricted list without gaining any affirmative permission to be compounded.

It had no active review pathway after that withdrawal. Scheduling it for the February 2027 meeting puts it back into formal consideration, alongside cathelicidin LL-37, GHK-Cu, dihexa acetate and PEG-MGF.

Being scheduled for review is not a status change, and it is not a signal about the outcome.

The dermatologic concern, precisely stated

This is where precision matters, because both the alarmist and the dismissive versions of this story are wrong.

Melanotan II stimulates melanocytes — all of them, including the melanocytes in existing moles. Published case reports have documented darkening of existing moles, the appearance of new nevi, and changes in mole shape and size during use. Case reports have also documented melanoma diagnosed in Melanotan II users, including lesions arising from pre-existing moles.

Case reports cannot establish causation. That is a genuine methodological limit, and anyone telling you this compound has been proven to cause melanoma is overstating the evidence.

But the concern dermatologists articulate is more specific than de novo cancer initiation. It is that stimulating melanocyte proliferation could accelerate the progression of already-abnormal cells — dysplastic nevi, melanocytes carrying early mutations — toward something worse. The pattern in the published case reports, melanoma arising from pre-existing lesions, is consistent with that concern.

The rest of the documented adverse effects

Beyond the pigmentary concerns, the published literature and case reports describe:

• Nausea — the most commonly reported effect.
• Facial flushing.
• Melanonychia — brown-to-black discoloration of one or more nails.
• New and atypical melanocytic naevi.
• Rhabdomyolysis — muscle breakdown, documented in case reports with muscle pain, dark urine and markedly elevated creatine kinase requiring hospitalization. Reported cases have sometimes involved confounding factors such as extreme exertion or dehydration.
• Cardiovascular effects — melanocortin receptors are expressed in cardiovascular tissue, and transient increases in blood pressure and heart rate have been reported.
• Sexual arousal effects — melanocortin agonism affects sexual function, which is the mechanism behind a separately developed and FDA-approved melanocortin drug for a different indication.

The supply problem sits on top of all of it

Melanotan II is overwhelmingly obtained through unregulated online sources. The Skin Cancer Foundation has made this point explicitly: consumers have no reliable way to know the purity, dosage or contents of what they are buying.

This compounds every risk above. An adverse effect could come from the peptide, from an impurity, from a contaminant, or from a dose that is not what the label claims. Nothing in that supply chain is designed to let you distinguish between those possibilities, and no one is checking.

It is also the exact issue FDA scientists raised repeatedly across the July 2026 review: inadequate characterization — being able to say reliably what is in a given preparation. That objection applies with more force here than almost anywhere else.

Why this matters more for some readers than others

Risk is not evenly distributed. The considerations weigh heavier if you have:

• A personal or family history of melanoma or other skin cancer;
• A high nevus count, or any known dysplastic or atypical moles;
• Fair skin, light eyes, or a history of significant sun exposure or tanning bed use;
• Any cardiovascular condition, particularly uncontrolled hypertension;
• Pregnancy or breastfeeding, where there is no safety data at all.

Notably, the demographic most drawn to tanning products overlaps substantially with the demographic already at elevated baseline melanoma risk. That overlap is part of why the case-report literature is difficult to interpret — and part of why caution is the reasonable default rather than an excess of it.

If you have used it

The reasonable step is a dermatologic examination, and it is reasonable regardless of how much you used or how long ago.

Bring the history explicitly. A dermatologist assessing pigmented lesions will interpret them differently knowing that melanocyte-stimulating exposure occurred, and that context changes what a given change in a mole means. Photographic documentation of existing moles is useful if you have it.

The ABCDE framework — asymmetry, border irregularity, color variation, diameter over six millimeters, and evolution or change — remains the standard self-screening heuristic. The relevant limitation is that Melanotan II use makes the color and evolution criteria harder to read.

What to watch

The February 2027 meeting date has not been posted. When it is announced, the FDA typically publishes briefing materials about two business days ahead, and those documents will contain the agency's own position on Melanotan II — which is the single most informative thing that will exist on this compound.

Expect the vote, whichever way it goes, to be marketed aggressively. A recommendation would concern whether the substance can be characterized and compounded safely in a pharmacy. It would not be a finding that tanning injections are safe, and it would not address a single one of the dermatologic concerns above.